Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 17 10 2020
accepted: 26 04 2021
pubmed: 9 5 2021
medline: 15 12 2021
entrez: 8 5 2021
Statut: ppublish

Résumé

Tumor infiltration by immunosuppressive myeloid cells or tumor-associated macrophages (TAMs) contributes to tumor progression and metastasis. In contrast to their adult counterparts, higher TAM signatures do not correlate with aggressive tumor behavior in pediatric brain tumors. While prominent TAM infiltrates exist before and after radiation, the degree to which irradiated macrophages and microglia support progression or leptomeningeal metastasis remains unclear. Patients with medulloblastoma often present with distant metastases and tumor recurrence is largely incurable, making them prime candidates for the study of novel approaches to prevent neuroaxis dissemination and recurrence. Macrophage depletion was achieved using CSF-1 receptor inhibitors (CSF-1Ri), BLZ945 and AFS98, with or without whole brain radiation in a variety of medulloblastoma models, including patient-derived xenografts bearing Group 3 medulloblastoma and a transgenic Sonic Hedgehog (Ptch1 Effective reduction of microglia, TAM, and spinal cord macrophage with CSF-1Ri resulted in negligible effects on the rate of local and spinal recurrences or survival following radiation. Results were comparable between medulloblastoma subgroups. While notably few tumor-infiltrating lymphocytes (TILs) were detected, average numbers of CD3+ TILs and FoxP3+ Tregs did not differ between groups following treatment and tumor aggressiveness by Ki67 proliferation index was unaltered. In the absence of other microenvironmental influences, medulloblastoma-educated macrophages do not operate as tumor-supportive cells or promote leptomeningeal recurrence in these models. Our data add to a growing body of literature describing a distinct immunophenotype amid the medulloblastoma microenvironment and highlight the importance of appropriate pediatric modeling prior to clinical translation.

Identifiants

pubmed: 33963961
doi: 10.1007/s11060-021-03767-x
pii: 10.1007/s11060-021-03767-x
pmc: PMC8248272
mid: NIHMS1712617
doi:

Substances chimiques

Hedgehog Proteins 0
Macrophage Colony-Stimulating Factor 81627-83-0
Receptor Protein-Tyrosine Kinases EC 2.7.10.1
Receptor, Macrophage Colony-Stimulating Factor EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

225-237

Subventions

Organisme : NIH HHS
ID : 2R01CA114567
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009351
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA114567
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA096832
Pays : United States
Organisme : NIH HHS
ID : 5T32CA009351
Pays : United States

Références

Chen JJW, Lin Y-C, Yao P-L, Yuan A, Chen H-Y, Shun C-T, Tsai M-F, Chen C-H, Yang P-C (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23(5):953–964. https://doi.org/10.1200/jco.2005.12.172
doi: 10.1200/jco.2005.12.172 pubmed: 15598976
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416. https://doi.org/10.1038/nrclinonc.2016.217
doi: 10.1038/nrclinonc.2016.217 pubmed: 28117416 pmcid: 5480600
Stafford JH, Hirai T, Deng L, Chernikova SB, Urata K, West BL, Brown JM (2016) Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol 18(6):797–806. https://doi.org/10.1093/neuonc/nov272
doi: 10.1093/neuonc/nov272 pubmed: 26538619
Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, Joyce JA (2017) Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene 36(43):6049–6058. https://doi.org/10.1038/onc.2017.261
doi: 10.1038/onc.2017.261 pubmed: 28759044 pmcid: 5666319
Palma MD, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3):277–286. https://doi.org/10.1016/j.ccr.2013.02.013
doi: 10.1016/j.ccr.2013.02.013 pubmed: 23518347
Poon CC, Sarkar S, Yong VW, Kelly JJP (2017) Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain 140(6):1548–1560. https://doi.org/10.1093/brain/aww355
doi: 10.1093/brain/aww355 pubmed: 28334886
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ (2011) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128(3):703–711. https://doi.org/10.1007/s10549-010-1154-y
doi: 10.1007/s10549-010-1154-y pubmed: 20842526
Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, Van Den Berg A, Gascoyne RD (2012) Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 120(17):3530–3540. https://doi.org/10.1182/blood-2012-06-439570
doi: 10.1182/blood-2012-06-439570 pubmed: 22955918
Zhu X-D, Zhang J-B, Zhuang P-Y, Zhu H-G, Zhang W, Xiong Y-Q, Wu W-Z, Wang L, Tang Z-Y, Sun H-C (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26(16):2707–2716. https://doi.org/10.1200/jco.2007.15.6521
doi: 10.1200/jco.2007.15.6521 pubmed: 18509183
Jia JB, Wang WQ, Sun HC, Zhu XD, Liu L, Zhuang PY, Zhang JB, Zhang W, Xu HX, Kong LQ, Lu L, Wu WZ, Wang L, Tang ZY (2010) High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist 15(7):732–743. https://doi.org/10.1634/theoncologist.2009-0170
doi: 10.1634/theoncologist.2009-0170 pubmed: 20551429 pmcid: 3228006
Plant AS, Koyama S, Sinai C, Solomon IH, Griffin GK, Ligon KL, Bandopadhayay P, Betensky R, Emerson R, Dranoff G, Kieran MW, Ritz J (2018) Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. https://doi.org/10.1007/s11060-017-2737-9
doi: 10.1007/s11060-017-2737-9 pubmed: 29322427
Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK (2013) Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol 191(9):4880–4888. https://doi.org/10.4049/jimmunol.1301966
doi: 10.4049/jimmunol.1301966 pubmed: 24078694
Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng H-K, Li X, Mu K, Trabelsi S, Brahim DHM-B, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, De Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily M-A, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, Von Bueren AO, Baudis M, Resnick A, Jones C (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32(4):520-537.e525. https://doi.org/10.1016/j.ccell.2017.08.017
doi: 10.1016/j.ccell.2017.08.017 pubmed: 28966033 pmcid: 5637314
Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, Resnick AC, Massimino M, Garrè ML, Smith H, Capper D, Pfister SM, Würdinger T, Tam R, Garcia J, Thakur MD, Vassal G, Grill J, Jaspan T, Varlet P, Jones C (2018) Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY Phase II Randomized Trial. Cancer Cell 33(5):829-842.e825. https://doi.org/10.1016/j.ccell.2018.04.004
doi: 10.1016/j.ccell.2018.04.004 pubmed: 29763623 pmcid: 5956280
Koschmann C, Bloom K, Upadhyaya S, Geyer JR, Leary SE (2016) Survival after relapse of medulloblastoma. J Pediatr Hematol Oncol 38(4):269–273. https://doi.org/10.1097/mph.0000000000000547
doi: 10.1097/mph.0000000000000547 pubmed: 26907655
Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, Massimino M, Navajas A, Von Hoff K, Rutkowski S, Warmuth-Metz M, Clifford SC, Pietsch T, Pizer B, Lannering B (2016) Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol 129(3):515–524. https://doi.org/10.1007/s11060-016-2202-1
doi: 10.1007/s11060-016-2202-1 pubmed: 27423645 pmcid: 5020107
Thomas PRM, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, Albright L, Allen JC, Packer RJ, Linggood R, Mulhern R, Stehbens JA, Langston J, Stanley P, Duffner P, Rorke L, Cherlow J, Friedman HS, Finlay JL, Vietti TJ, Kun LE (2000) Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18(16):3004–3011. https://doi.org/10.1200/jco.2000.18.16.3004
doi: 10.1200/jco.2000.18.16.3004 pubmed: 10944134
Wang S-C, Yu C-F, Hong J-H, Tsai C-S, Chiang C-S (2013) Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS ONE 8(8):e69182. https://doi.org/10.1371/journal.pone.0069182
doi: 10.1371/journal.pone.0069182 pubmed: 23940516
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694–705. https://doi.org/10.1172/jci40283
doi: 10.1172/jci40283 pubmed: 20179352 pmcid: 20179352
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19(10):1264–1272. https://doi.org/10.1038/nm.3337
doi: 10.1038/nm.3337 pubmed: 24056773 pmcid: 3840724
Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L (2013) CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 73(9):2782–2794. https://doi.org/10.1158/0008-5472.can-12-3981
doi: 10.1158/0008-5472.can-12-3981 pubmed: 4097014 pmcid: 4097014
Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, De Groot M, Quail DF, Tillard L, Gadiot J, Huse JT, Brandsma D, Westerga J, Watts C, Joyce JA (2020) Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med 12(552):eaaw7843. https://doi.org/10.1126/scitranslmed.aaw7843
doi: 10.1126/scitranslmed.aaw7843 pubmed: 32669424
Hume DA, Macdonald KPA (2012) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119(8):1810–1820. https://doi.org/10.1182/blood-2011-09-379214
doi: 10.1182/blood-2011-09-379214 pubmed: 22186992
Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MHJ, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT (2005) Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. PNAS 102(44):16078–16083. https://doi.org/10.1073/pnas.0502000102
doi: 10.1073/pnas.0502000102 pubmed: 16249345
Webb MW, Sun J, Sheard MA, Liu WY, Wu HW, Jackson JR, Malvar J, Sposto R, Daniel D, Seeger RC (2018) C olony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer 143(6):1483–1493. https://doi.org/10.1002/ijc.31532
doi: 10.1002/ijc.31532 pubmed: 29665011 pmcid: 6105468
Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS (2019) Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol 11:175883591985423. https://doi.org/10.1177/1758835919854238
doi: 10.1177/1758835919854238
Carola M, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Leon FF, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Ingo WA, Abiraj K, Philippe SA, Gomez-Roca C, Karin IA, Christophe D-P, Levitsky H, Blay J-Y, Rüttinger D (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6):846–859. https://doi.org/10.1016/j.ccr.2014.05.016
doi: 10.1016/j.ccr.2014.05.016
Brabetz S, Leary SES, Gröbner SN, Nakamoto MW, Şeker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, Mack NL, Pakiam F, Schwalm B, Korshunov A, Balasubramanian GP, Northcott PA, Pedro KD, Dey J, Hansen S, Ditzler S, Lichter P, Chavez L, Jones DTW, Koster J, Pfister SM, Kool M, Olson JM (2018) A biobank of patient-derived pediatric brain tumor models. Nat Med 24(11):1752–1761. https://doi.org/10.1038/s41591-018-0207-3
doi: 10.1038/s41591-018-0207-3 pubmed: 30349086
Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T (2004) Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/−p53−/− mice. Cancer Cell 6(3):229–240. https://doi.org/10.1016/j.ccr.2004.08.019
doi: 10.1016/j.ccr.2004.08.019 pubmed: 15380514
Chen Y-F, Fu L-W (2011) Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm 1(4):197–207. https://doi.org/10.1016/j.apsb.2011.10.007
doi: 10.1016/j.apsb.2011.10.007
Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y-S (2018) Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. https://doi.org/10.1186/s12943-018-0801-5
doi: 10.1186/s12943-018-0801-5 pubmed: 30217192
Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64(19):7022–7029. https://doi.org/10.1158/0008-5472.can-04-1449
doi: 10.1158/0008-5472.can-04-1449 pubmed: 15466195
Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2):263–266. https://doi.org/10.1016/j.cell.2006.01.007
doi: 10.1016/j.cell.2006.01.007
Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE (2012) Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 18(3):519–527. https://doi.org/10.2119/molmed.2011.00217
doi: 10.2119/molmed.2011.00217 pubmed: 22294205
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408–1414. https://doi.org/10.1200/jco.2009.27.4324
doi: 10.1200/jco.2009.27.4324 pubmed: 20823417
Margol AS, Robison NJ, Gnanachandran J, Hung LT, Kennedy RJ, Vali M, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S (2015) Tumor-associated macrophages in SHH subgroup of medulloblastomas. Clin Cancer Res 21(6):1457–1465. https://doi.org/10.1158/1078-0432.ccr-14-1144
doi: 10.1158/1078-0432.ccr-14-1144 pubmed: 25344580
Michele C (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3):277–286. https://doi.org/10.1016/j.ccr.2013.02.013
doi: 10.1016/j.ccr.2013.02.013
Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. https://doi.org/10.1016/j.cell.2010.03.014
doi: 10.1016/j.cell.2010.03.014 pubmed: 20371344 pmcid: 4994190
Lieberman NAP, Degolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, Leary SES, Crane CA (2019) Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol 21(1):83–94. https://doi.org/10.1093/neuonc/noy145
doi: 10.1093/neuonc/noy145 pubmed: 30169876
Maximov V, Chen Z, Wei Y, Robinson MH, Herting CJ, Shanmugam NS, Rudneva VA, Goldsmith KC, Macdonald TJ, Northcott PA, Hambardzumyan D, Kenney AM (2019) Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nat Commun. https://doi.org/10.1038/s41467-019-10458-9
doi: 10.1038/s41467-019-10458-9 pubmed: 31375688
Wes PD, Holtman IR, Boddeke EWGM, Möller T, Eggen BJL (2016) Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia 64(2):197–213. https://doi.org/10.1002/glia.22866
doi: 10.1002/glia.22866 pubmed: 26040959
Peng X (2019) Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF1-R, in FGFR-dependent and macrophage-dominant cancer models. J Exp Clin Cancer Res. https://doi.org/10.1186/s13046-019-1357-y
doi: 10.1186/s13046-019-1357-y pubmed: 31805977
Quintana E, Schulze CJ, Myers DR, Choy TJ, Mordec K, Wildes D, Tobvis Shifrin N, Belwafa A, Koltun ES, Gill AL, Singh M, Kelsey S, Goldsmith MA, Nichols R, Smith JAM (2020) Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment. Cancer Res. https://doi.org/10.1158/0008-5472.can-19-3038
doi: 10.1158/0008-5472.can-19-3038 pubmed: 32393663 pmcid: 7335354
Endersby R, Whitehouse J, Pribnow A, Kuchibhotla M, Hii H, Carline B, Gande S, Stripay J, Ancliffe M, Howlett M, Schoep T, George C, Andradas C, Dyer P, Schluck M, Patterson B, Tacheva-Gigorova SK, Cooper MN, Robinson G, Stewart C, Pfister SM, Kool M, Milde T, Gajjar A, Johns T, Wechsler-Reya RJ, Roussel MF, Gottardo NG (2021) Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med 13(577):eaba7401. https://doi.org/10.1126/scitranslmed.aba7401
doi: 10.1126/scitranslmed.aba7401 pubmed: 33472956
Shankarappa PS, Peer CJ, Odabas A, McCully CL, Garcia RC, Figg WD, Warren KE (2020) Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. Cancer Chemother Pharmacol 85(5):1003–1007. https://doi.org/10.1007/s00280-020-04071-7
doi: 10.1007/s00280-020-04071-7 pubmed: 32306101
Monica A, Maya N, Elizabeth R, Kitazawa M, Matusow B, Nguyen H, Brian K (2014) Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82(2):380–397. https://doi.org/10.1016/j.neuron.2014.02.040
doi: 10.1016/j.neuron.2014.02.040
Rice RA, Pham J, Lee RJ, Najafi AR, West BL, Green KN (2017) Microglial repopulation resolves inflammation and promotes brain recovery after injury. Glia 65(6):931–944. https://doi.org/10.1002/glia.23135
doi: 10.1002/glia.23135 pubmed: 28251674 pmcid: 5395311
Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel JA, Reynolds CP (2012) Novel cell lines established from pediatric brain tumors. J Neurooncol 107(2):269–280
doi: 10.1007/s11060-011-0756-5
Smith KS, Xu K, Mercer KS, Boop F, Klimo P, Decupyere M, Grenet J, Robinson S, Dunphy P, Baker SJ, Ellison DW, Merchant TE, Upadayaya SA, Gajjar A, Wu G, Orr BA, Robinson GW, Northcott PA, Roussel MF (2020) Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathol 140(2):209–225. https://doi.org/10.1007/s00401-020-02171-5
doi: 10.1007/s00401-020-02171-5 pubmed: 32519082 pmcid: 7360541

Auteurs

Erin E Crotty (EE)

Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. Erin.Crotty@fredhutch.org.
Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA. Erin.Crotty@fredhutch.org.

Stephanie M C Smith (SMC)

Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Medtronic, Department of Clinical Strategy, 1775, Pyramid Place TN03, Memphis, TN, 38132, USA.

Ken Brasel (K)

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Century Therapeutics, 3675 Market St., Philadelphia, PA, 19104, USA.

Fiona Pakiam (F)

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.

Emily J Girard (EJ)

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.

Yamicia D Connor (YD)

Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA.

Frederique Zindy (F)

Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Andrew J Mhyre (AJ)

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.

Martine F Roussel (MF)

Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

James M Olson (JM)

Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH